Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01216293 · ClinicalTrials.gov registry record · Phase 1
Effect of Dexlansoprazole on Bone Homeostasis
A Phase 1 study of Bone and Bones and Homeostasis, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
- 12
- Study locations
NCT01216293 is a Phase 1 study of Bone and Bones and Homeostasis that has completed, run by Takeda. The registered enrollment target is 115 participants. The trial reports 12 study locations across 9 states.
The verdict
NCT01216293, a Phase 1 study of Bone and Bones and Homeostasis, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of dexlansoprazole modified release (MR), once daily (QD), on bone homeostasis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Esomeprazole
- DRUG Dexlansoprazole
Study Locations (12)
California
- - San Diego
- - Walnut Creek
Florida
- - Hialeah
- - Jupiter
Texas
- - Austin
- - San Antonio
Colorado
- - Lakewood
Maryland
- - Bethesda
New Mexico
- - Albuquerque
South Carolina
- - Spartanburg
Washington
- - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2010-11-01 |
| Est. Completion | 2015-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01216293
The ClinicalTrials.gov registry entry for NCT01216293 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bone and Bones appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01216293 reports 12 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT01216293 about?
NCT01216293 is a clinical study titled "Effect of Dexlansoprazole on Bone Homeostasis". The purpose of this study is to evaluate the effect of dexlansoprazole modified release (MR), once daily (QD), on bone homeostasis.
What is the current status of trial NCT01216293?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2010-11-01. Estimated completion is 2015-02-01.
What conditions does trial NCT01216293 study?
This clinical trial studies the following conditions: Bone and Bones, Homeostasis.
What interventions are being tested in trial NCT01216293?
The interventions under investigation include: Placebo (DRUG), Esomeprazole (DRUG), Dexlansoprazole (DRUG).
Who is sponsoring clinical trial NCT01216293?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01216293 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Maryland, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone and Bones
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.